Know More About “Viral Vectors And Plasmid DNA Manufacturing Market 2022-2030” Growth Worldwide…Posted by Mrudula Karmarkar on August 11th, 2022 The global viral vectors and plasmid DNA manufacturing market are expected to reach USD 11.19 billion by 2030, registering a CAGR of 14.71% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growing demand for viral vectors and plasmid DNA for gene therapy has prompted leading market participants to introduce innovative and technologically advanced programs and technologies to increase plasmid DNA production. For instance, In April 2018, GE Healthcare Life Sciences announced the introduction of KUBio BSL 2, a prefabricated, modular bioprocessing facility for the manufacturing of viral vector-based vaccinations, oncolytic virus, and cell and gene therapies. The government investments in the development of novel technologies and production facilities are expanding. For instance, in 2018, the Department for Business, Energy, and Industrial Strategy granted Cobra Biologics a US$ 3.4 million Industrial Strategy Challenge Fund grant for infrastructure investment to expand production capabilities and commercialization of DNA and viral vector products. As a result, growing government spending on research & development is likely to propel market expansion throughout the forecast period. The market growth is being fueled by an increase in the global prevalence of cancer and the availability of sophisticated healthcare facilities. As per GLOBOCAN 2020, there have been 1,92,92,789 new cancer cases in 2020, with the number expected to rise to 2,88,87,940 by 2040. Furthermore, suicide gene therapy, therapeutic gene vaccines, oncolytic virotherapy, and anti-angiogenesis are just a few of the gene therapy treatments that have been developed to treat a variety of tumors. Therefore, it will increase the demand for gene therapy and further boost market growth. As numerous recombinant proteins, live attenuated viruses, and nucleic acid-based vaccines are under pre-clinical development for the treatment of the diseases, this pandemic is likely to create future growth prospects for the global market. Furthermore, viral vector vaccines are made up of a recombinant virus that has been attenuated to minimize pathogenicity, and genes expressing viral antigen(s) that have been cloned using recombinant DNA technologies. Moreover, key players in the viral vector manufacturing industry are expanding their production capacities. For instance, in January 2021, Johnson & Johnson revealed positive efficacy and safety results for COVID-19 from its Phase 3 ENSEMBLE clinical study, which used its AdVac vaccination platform. All preconditions and targets were met for its single-dose COVID-19 vaccine, which is now under development at Janssen Pharmaceutical Companies. The AdVac viral vector technology has the potential to give the body a powerful and long-lasting humoral and cellular immune response. Furthermore, the Oxford-AstraZeneca COVID-19 vaccine is another viral vector-based vaccination that has obtained many approvals. The vaccine was discovered in November 2020 and has since been mass-produced for public vaccination. Thus, it will boost market growth. To Request Sample Copy of this report, click the link: https://www.grandviewresearch.com/industry-analysis/viral-vector-manufacturing-market/request/rs1 Viral vectors are tools for delivering genetic material into cells. Viruses have developed specific systems for transporting their DNA inside the cells they infect. Furthermore, retrovirus, adenovirus, lentivirus, herpes simplex virus, and others are among the viral vectors which can be employed to transfer genetic material into the genetic composition of cells. The viral vectors and plasmid DNA manufacturing market saw a lucrative opportunity due to the COVID-19 pandemic. Furthermore, the market players are shifting their business focus toward the development of viral vectors for the SARS-CoV-2 vaccine. Viral vectors are commonly employed tools used in the discovery and development of vaccines against SARS-CoV-2. The ongoing COVID-19 pandemic has encouraged investment in this space in search of a vaccine as viral vector-based vaccines can be manufactured and designed relatively quickly with the use of the same building blocks. For instance, Companies such as Johnson and Johnson/Janssen (J&J); AstraZeneca/University of Oxford; Gamaleya Research Institute; and CanSino Biologics have developed viral vector-based vaccines. Viral Vectors And Plasmid DNA Manufacturing Market Report Highlights
The market for viral vectors and plasmid DNA manufacturing is highly competitive with the presence of well-established as well as small and mid-sized emerging players. A prominent number of players are rapidly opting for geographical expansion, strategic collaborations, and partnerships through mergers and acquisitions in emerging and economically favorable regions. For Instance, Cobra Bio focuses on the manufacturing of scalable, and robust process strategies for the manufacture of a viral vector. The company is active in the production of lentiviral vectors, AAV, and adenoviruses. Moreover, in January 2021, Cobra Biologics expanded its manufacturing facilities in Europe and the U.S. It includes the expansion of the HQ DNA manufacturing facility by four times and new facilities in Europe. This enhanced the company’s position in the market. Some of the key players in the global viral vectors and plasmid DNA manufacturing market include:
Like it? Share it! More by this author |